跳至主要内容
临床试验/ACTRN12615001152516
ACTRN12615001152516
招募中
未知

Feasibility study: Targeting post cancer fatigue among women and men with breast cancer using acupuncture compared with treatment as usual

Western Sydney University0 个研究点目标入组 20 人2015年10月29日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
未指定
发起方
Western Sydney University
入组人数
20
状态
招募中
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2015年10月29日
结束日期
待定
最后更新
6年前
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • 1\) diagnosis of stage I, II, or III BC, who have completed breast surgery, adjuvant or neo\-adjuvant chemotherapy and/or adjuvant radiotherapy between one month to 2 years prior to enrolment and who have not developed recurrent disease in the intervening period between diagnosis and study recruitment.
  • 2\) Taking adjuvant endocrine therapy and trastuzumab (Herceptin) are eligible
  • 3\) Ongoing cancer related fatigue, defined as a score of 4 or more on the fatigue sub scale of the Somatic and Psychological Health Report (SPHERE) questionnaire
  • 4\) Normal coagulation coagulation studies: PT, APTT, INR at baseline or within the previous 1 month.
  • 5\) Adequate haematological parameters at baseline or within the previous 1 month: Hb greater than 100, ANC greater than 1\.0, Platelet count greater than 150\.

排除标准

  • 1\) Co\-morbid medical conditions expected to cause ongoing fatigue, (e.g.co\-morbidity significant anaemia (defined as Hb less than 100\) or thyroid disease) as assessed by the investigator.
  • 2\) Current use of acupuncture.
  • 3\) Needle phobia.
  • 4\) Concurrent treatment with medication interfering with blood clotting or bleeding time, including heparin and fractionated heparin, vitamin K antagonists, direct thrombin inhibiitors, factor Xa inhibitors, and antiplatelet agents.
  • 5\) Life expectancy less than six months.
  • 6\) Plan for major surgery during the time of the study e.g. breast reconstruction or re\-excision.
  • 7\) History of other malignany within 5 years of recruitment, other than CIN of cervix or non\-melanomatous skin cancers.

结局指标

主要结局

未指定

相似试验